Short Stature Treatment & Management

Updated: Feb 23, 2017
  • Author: Sunil Kumar Sinha, MD; Chief Editor: Robert P Hoffman, MD  more...
  • Print
Treatment

Medical Care

Medical care depends on the etiology of the short stature.

Recombinant human growth hormone (rhGH) administration has not been proven to remarkably improve final adult height in children with normal variant short stature. [2, 3] Published clinical studies that have focused on this particular issue have been inconclusive. These reports were flawed because of the following:

  • Selection bias due to high drop-out rates from treatment regimens (presumably due, in part, to the parents' or health care provider's dissatisfaction with results of therapy in these individuals)
  • Lack of key design elements for a proper clinical trial (eg, placebo controls, double blinding, randomization)
  • Inadequate follow-up study to final adult height

A double-blinded, randomized study from the National Institutes of Health suggests GH has a small effect on adult height in children with normal short stature if they are treated with GH injections for many years. [8] Other randomized studies have shown variable results, with some demonstrating benefit [9]  and others not. [10, 11]  A study by Schena et al indicated that in children with short stature who are not GH deficient (ie, those with idiopathic short stature), long-term treatment with rhGH yields results similar to those in GH-deficient children who undergo this therapy, although this study did not have an untreated control group and pretreatment growth velocity data for the patients was missing. [12]  Thus, the risk-benefit ratio for treatment of children with idiopathic short stature is not well defined. 

There is also controversy regarding GH dosing. Fixed dosing based on weight has long been used. However, a 2-year, open-label, randomized trial that measured the response to somatotropin (rDNA origin) therapy based on serum insulinlike growth factor-I (IGF-I) levels in children with GH deficiency and in children with idiopathic short stature suggested that IGF-based dosing of GH may safely provide superior growth outcome in both groups. [13]

Recombinant human GH has been used for over 4 decades, with a good track record of safety. A preliminary report from the French part of the European Union Safety and Appropriateness of GH treatments in Europe (EU SAGhE) study showed increased overall mortality in adults treated with rhGH during childhood, raising concerns about the long-term safety of this therapy. [14] Data from Belgium, The Netherlands, and Sweden, however, did not show a similar distribution of causes of death. [15] After reviewing information from the EU SAGhE study and other sources, the US Food and Drug Administration (FDA) recommended continued rhGH prescription and use according to the labeled recommendations. [16]

Next:

Surgical Care

Surgical care depends on the underlying cause of short stature. Brain tumors that cause hyposomatotropism may require neurosurgical intervention, depending on the tumor type and location (see Hyposomatotropism). Limb-lengthening procedures have been performed but carry enormous morbidity and mortality risks and are not recommended.

Previous
Next:

Consultations

The following consultations are indicated:

  • Consult a pediatric cardiologist, radiologist, and audiologist for patients with Ullrich-Turner syndrome.
  • Consult a psychologist for patients with eating disorders.
  • Perform all GH provocative testing under the supervision of a pediatric endocrinologist.
Previous
Next:

Diet

Optimize nutrition in patients with GI disease. Obtain psychologic or psychiatric consultation for patients with eating disorders. Forced energy intake in children with normal variant short stature has not been demonstrated to improve short-term growth or final adult height.

Previous
Next:

Activity

Do not restrict activity in children with normal variant short stature.

Previous
Next:

Complications

Short stature may be the harbinger of an occult chronic disease of childhood. Normal variant short stature may be associated with a bone mineral density that is lower than in the remainder of the (taller) population. Whether this healthy subset of the population is at higher risk of osteoporosis remains unclear.

Previous
Next:

Prevention

Growth evaluation is a useful means of detecting chronic disease in children.

Previous
Next:

Long-Term Monitoring

The proper evaluation of short stature is conducted in an outpatient setting with a calibrated stadiometer. The most useful information in the evaluation of a child with short stature is the child's growth pattern (see image below).

Comparison of the growth patterns between idiopath Comparison of the growth patterns between idiopathic short stature and constitutional growth delay.

In children younger than 3 years, track length and weight at 3-month intervals. Standing height and weight can be tracked at 6-month intervals in older children.

Previous